Head of Public Affairs
Mobile: +61 409 978 314
45 Poplar Rd, Parkville
Victoria 3052 Australia
AFSTYLA® (rFVIII-Single Chain) – FDA approval
CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemophilic Factor (Recombinant), Single Chain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.
FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) - FDA Approval
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved Seqirus’ FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
IDELVION® (rFIX-FP) - European Commission Approval
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that, following the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation to grant marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B in late February 2016, the European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Expanded Bio21 to house global research hub
The University of Melbourne’s internationally recognized Bio21 Molecular Science and Biotechnology Institute is to be substantially expanded and will house CSL’s Global Research and Translational Medicine Hub.
IDELVION® (rFIX-FP) – FDA approval
CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring’s novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B.
IDELVION® (rFIX-FP) - CHMP recommendation
CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION®
(Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B.
CSL Appoints New Director
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that Dr Megan Clark AC has been appointed as a Director of the Company effective from 16 February 2016.
Half Year Result 2016 CSL Delivers Exceptional Performance
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1
NPAT grew 7% and EPS grew 9%, at constant currency2
CSL brands world’s no. 2 influenza vaccine provider as Seqirus
Global biotherapeutics leader CSL Limited announced that its influenza vaccines business will begin operating under the brand Seqirus effective today, following the merger of the recently-acquired Novartis influenza business and its existing vaccines and pharmaceutical business bioCSL.
CSL Welcomes New Lifetime Immunisation Register
CSL congratulates the Federal Government on the successful passage
of legislation to establish an Australian Immunisation Register (AIR). The new register, which
will be progressively introduced, will capture all vaccines that Australians receive from birth to
CSL Names David Lamont as Chief Financial Officer
CSL today named Mr. David Lamont, an accomplished global financial leader with a diverse commercial background, as its Chief Financial Officer (CFO), effective 2 January 2016. He will be based at CSL’s headquarters in Parkville, Australia. As announced in August, CSL CFO Mr. Gordon Naylor is transitioning to the role of President of Seqirus, the new global business created from the integration of bioCSL and the newly acquired Novartis influenza vaccines business.
CSL standing firm on Enterprise Agreement Offer
Union demands for a pay rise of 11.5% over 3 years are not sustainable says CSL as it
prepares to put its offer of a 9.75% wage increase to an employee vote for the second
time. Unions are instructing employees to hold out for more while ongoing industrial
action starts to impact the export of haemophilia products into Europe.
Strong Full Year Result
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,379 million for the full year ended 30 June 2015, up 6% on a reported basis when compared to the prior comparable period (PCP). NPAT grew 10% on a constant currency1
basis, after adjusting for the one-off costs2
associated with the acquisition of the Novartis influenza vaccine business.
CSL Supports New Medical Research Future Fund
Melbourne, Australia – CSL told the Senate Inquiry into the Medical Research Future Fund (MRFF) in Melbourne today that it was strongly supportive of the new fund and saw it as an acknowledgement of the significant economic benefits that Australia derives from investment in medical research.
Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus.
Competitive Advanced Manufacturing - Quite within Reach for Australia
Securing a globally competitive locally-based advanced manufacturing sector is quite within reach for Australia, according to CSL Limited, Australia’s largest biotechnology company. The key is to make a serious, strategic effort to attract footloose global investment, especially targeting innovations and ideas developed in Australia.
CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that CSL Behring will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of investigational and branded products at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress being held in Toronto June 20 through 25. The presentations will include pivotal trial data for two of its late-stage recombinant products – its novel recombinant factor VIII SingleChain (rVIII-SingleChain) compound for hemophilia A and its long-acting recombinant factor IX albumin fusion protein (rIX-FP) for hemophilia B.
Gordon Naylor to lead CSL’s Global Influenza Vaccine Business
CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Gordon Naylor will lead CSL’s new global influenza vaccine business, which is planned for launch at the start of 2016. Mr Naylor is currently the Company’s Chief Financial Officer and has held executive management responsibility for CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012.
Half Year Result 2015
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$692 million for the six months ended 31 December 2014, up US$47 million or 7% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 10%.
CSL Welcomes China Entrepreneur Club Delegation
CSL Limited (ASX:CSL) today welcomed a delegation from the China Entrepreneur Club (CEC), the premier business leader platform in China, to their Broadmeadows site in Melbourne. The visit provided an opportunity to share
knowledge, experiences and explore collaborative opportunities.
Prior Archived Newsroom
|Media Enquiries - CSL Limited|
Senior Director Public Affairs
Phone: +613 9389 3425
Mobile: +61 409 978 314
45 Poplar Rd, Parkville